We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
First Wave Bio Inc., today announced that it has received regulatory approval to begin clinical testing of its lead product candidate (FW-424) for the treatment of ulcerative colitis (UC).